ClinicalTrials.gg
CompletedNCT00658619Updated Aug 21, 2018Results posted

Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)

A Phase 2 interventional study of 400 µg Brimonidine Tartrate Implant and 200 µg Brimonidine Tartrate Implant in Macular Degeneration, sponsored by Allergan. Completed at 7 sites in 7 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-08-21.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Macular Degeneration by AbbVie — 3 open to participants now, 6 under way, 3 of them phase 3. Macular Degeneration · AbbVie.

Enrollment
12th of 22
119 · median 122
Started
2008
with 1 other
Phase 2
12 of 22
1 open now
Registered
4th of 22
by date

Among the 22 studies in Macular Degeneration by AbbVie, this one is the 12th largest by enrollment, is one of 2 that started in 2008, is one of 12 in phase 2, and was the 4th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 22 studies in Macular Degeneration by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Macular Degeneration by AbbVie, or all of them as a file.
02

Study summary

Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal implant. Patients will receive implant in one eye and "sham" treatment (meaning no treatment) in the fellow eye. Stage 2 will begin after 1 month of safety has been evaluated for Stage 1. Stage 2 is a randomized, double-masked, dose-response, sham-controlled evaluation of the safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy from age-related macular degeneration. Patients will be followed for up to 2 years.

03

Conditions studied

  • Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Geographic atrophy in both eyes due to age-related macular degeneration
  • Visual acuity between 20/40 to 20/320

Exclusion criteria

Exclusion Criteria:

  • Known allergy to brimonidine
  • Uncontrolled systemic disease or infection of the eye
  • Recent eye surgery or injections in the eye
  • Female patients who are pregnant, nursing or planning a pregnancy
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Other
    400 µg Brimonidine Tartrate Implant Stage 1

    Stage 1: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.

    Drug: 400 µg Brimonidine Tartrate Implant · Other: Sham (no implant)

  • Other
    200 µg Brimonidine Tartrate Implant Stage 1

    Stage 1: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.

    Drug: 200 µg Brimonidine Tartrate Implant · Other: Sham (no implant)

  • Other
    400 µg Brimonidine Tartrate Implant Stage 2

    Stage 2: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.

    Drug: 400 µg Brimonidine Tartrate Implant · Other: Sham (no implant)

  • Other
    200 µg Brimonidine Tartrate Implant Stage 2

    Stage 2: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.

    Drug: 200 µg Brimonidine Tartrate Implant · Other: Sham (no implant)

  • Sham comparator
    Sham (no implant) Stage 2

    Stage 2: sham in both eyes on Day 1 and Month 6.

    Other: Sham (no implant)

Interventions

  • 400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.

    Also known as: Brimonidine Tartrate PS DDS®

  • 200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.

    Also known as: Brimonidine Tartrate PS DDS®

  • OtherSham (no implant)

    Sham in one or both eyes on Day 1 and Month 6.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye

    Change from baseline in size of geographic atrophy lesion area in the study eye is based on fundus photography as read by an independent Reading Center. Photographs are taken with a specialized microscope with an attached camera to photograph the interior of the eye, including the retina and optic disc. A positive change from baseline indicates an increase in size of geographic atrophy lesion area (worsening; disease progression). Data are reported in disc area where 1 disc area = 1.767 millimeters squared (mm\^2).

    Time frame: Baseline, Month 12

Secondary outcomes

  1. Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye

    Change from baseline in size of geographic atrophy lesion area in the study eye is based on fundus photography as read by an independent Reading Center. Photographs are taken with a specialized microscope with an attached camera to photograph the interior of the eye, including the retina and optic disc. A positive change from baseline indicates an increase in size of geographic atrophy lesion area (worsening; disease progression). Data are reported in disc area where 1 disc area = 1.767 millimeters squared (mm\^2).

    Time frame: Baseline, Month 3, Month 6, Month 9, Month 18, Month 24

  2. Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

    BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

    Time frame: Baseline, 24 Months

  3. Change From Baseline in Contrast Sensitivity in the Study Eye

    Change from baseline in contrast sensitivity in the study eye is measured using a Pelli-Robson contrast sensitivity chart at 1 meter. The contrast sensitivity chart contains letters that are darkest at the top and then get progressively lighter. Scores range from 0 to 48 and are based on the number of letters read correctly. A negative change from baseline indicates a worsening in contrast sensitivity and a positive change from baseline indicates an improvement.

    Time frame: Baseline, 24 Months

  4. Change From Baseline in Reading Speed in the Study Eye

    Change from baseline in reading speed in the study eye is assessed using modified Bailey-Lovie word charts. Patients read the chart for 2 minutes and the numbers of words read correctly per minute are totaled. An increase in the number of words read correctly indicates an improvement and a decrease in the number of words read correctly indicates a worsening.

    Time frame: Baseline, 24 Months

07

Results

Posted Apr 26, 2013

Participant flow

Participant flow — Overall Study
Milestone400 µg Brimonidine Tartrate Implant Stage 1200 µg Brimonidine Tartrate Implant Stage 1400 µg Brimonidine Tartrate Implant Stage 2200 µg Brimonidine Tartrate Implant Stage 2Sham (no Implant) Stage 2
Started33414923
Completed32313721
Not completed0110122

Outcome measures

PrimaryChange From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye

Change from baseline in size of geographic atrophy lesion area in the study eye is based on fundus photography as read by an independent Reading Center. Photographs are taken with a specialized microscope with an attached camera to photograph the interior of the eye, including the retina and optic disc. A positive change from baseline indicates an increase in size of geographic atrophy lesion area (worsening; disease progression). Data are reported in disc area where 1 disc area = 1.767 millimeters squared (mm\^2).

Time frame:
Baseline, Month 12
Reported as:
Mean · Disc Area
Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye
Disc Area400 µg Brimonidine Tartrate Implant Stage 2200 µg Brimonidine Tartrate Implant Stage 2Sham (no Implant) Stage 2
Baseline6.219 ± 3.95246.897 ± 4.63975.526 ± 4.7890
Change from Baseline at Month 120.898 ± 0.75201.006 ± 0.78581.239 ± 1.1645
SecondaryChange From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye

Change from baseline in size of geographic atrophy lesion area in the study eye is based on fundus photography as read by an independent Reading Center. Photographs are taken with a specialized microscope with an attached camera to photograph the interior of the eye, including the retina and optic disc. A positive change from baseline indicates an increase in size of geographic atrophy lesion area (worsening; disease progression). Data are reported in disc area where 1 disc area = 1.767 millimeters squared (mm\^2).

Time frame:
Baseline, Month 3, Month 6, Month 9, Month 18, Month 24
Reported as:
Mean · Disc Area
Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye
Disc Area400 µg Brimonidine Tartrate Implant Stage 2200 µg Brimonidine Tartrate Implant Stage 2Sham (no Implant) Stage 2
Baseline6.219 ± 3.95246.897 ± 4.63975.526 ± 4.7890
Change from Baseline at Month 30.182 ± 0.33530.117 ± 0.66120.399 ± 0.3713
Change from Baseline at Month 60.482 ± 0.63250.570 ± 0.57490.609 ± 0.5474
Change from Baseline at Month 90.641 ± 0.68470.798 ± 0.64240.857 ± 0.7267
Change from Baseline at Month 181.306 ± 1.01641.413 ± 1.02911.697 ± 1.4185
Change from Baseline at Month 241.744 ± 1.40101.991 ± 1.44692.178 ± 1.7042
SecondaryChange From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye

BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.

Time frame:
Baseline, 24 Months
Reported as:
Mean · Number of Letters Read Correctly
Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
Number of Letters Read Correctly400 µg Brimonidine Tartrate Implant Stage 2200 µg Brimonidine Tartrate Implant Stage 2Sham (no Implant) Stage 2
Baseline54.8 ± 12.8952.1 ± 13.9153.7 ± 10.71
Change from Baseline at 24 Months-5.0 ± 13.77-3.2 ± 12.87-3.3 ± 12.98
SecondaryChange From Baseline in Contrast Sensitivity in the Study Eye

Change from baseline in contrast sensitivity in the study eye is measured using a Pelli-Robson contrast sensitivity chart at 1 meter. The contrast sensitivity chart contains letters that are darkest at the top and then get progressively lighter. Scores range from 0 to 48 and are based on the number of letters read correctly. A negative change from baseline indicates a worsening in contrast sensitivity and a positive change from baseline indicates an improvement.

Time frame:
Baseline, 24 Months
Reported as:
Mean · Number of Letters Read Correctly
Change From Baseline in Contrast Sensitivity in the Study Eye
Number of Letters Read Correctly400 µg Brimonidine Tartrate Implant Stage 2200 µg Brimonidine Tartrate Implant Stage 2Sham (no Implant) Stage 2
Baseline23.7 ± 5.6022.1 ± 5.7621.7 ± 7.56
Change from Baseline at 24 Months-0.9 ± 4.331.1 ± 7.220.6 ± 7.49
SecondaryChange From Baseline in Reading Speed in the Study Eye

Change from baseline in reading speed in the study eye is assessed using modified Bailey-Lovie word charts. Patients read the chart for 2 minutes and the numbers of words read correctly per minute are totaled. An increase in the number of words read correctly indicates an improvement and a decrease in the number of words read correctly indicates a worsening.

Time frame:
Baseline, 24 Months
Reported as:
Mean · Words per Minute (wpm)
Change From Baseline in Reading Speed in the Study Eye
Words per Minute (wpm)400 µg Brimonidine Tartrate Implant Stage 2200 µg Brimonidine Tartrate Implant Stage 2Sham (no Implant) Stage 2
Baseline10.21 ± 8.5329.62 ± 9.2248.72 ± 6.832
Change from Baseline at 24 Months-1.15 ± 5.527-0.28 ± 7.0350.45 ± 4.705

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
400 µg Brimonidine Tartrate Implant—14/43 (32.6%)38/43 (88.4%)
200 µg Brimonidine Tartrate Implant—20/51 (39.2%)47/51 (92.2%)
Sham (no Implant) Stage 2—9/23 (39.1%)20/23 (87%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
Event400 µg Brimonidine Tartrate Implant200 µg Brimonidine Tartrate ImplantSham (no Implant) Stage 2
Spinal Compression FractureInjury, poisoning and procedural complications0/430/512/23
AnaemiaBlood and lymphatic system disorders0/431/511/23
Acute Myocardial InfarctionCardiac disorders1/431/511/23
Atrial FibrillationCardiac disorders1/431/511/23
Gastrointestinal HaemorrhageGastrointestinal disorders0/430/511/23
PneumoniaInfections and infestations1/431/511/23
Clostridium Difficile ColitisInfections and infestations0/430/511/23
DiverticulitisInfections and infestations0/430/511/23
Urinary Tract Infection BacterialInfections and infestations0/430/511/23
Hip FractureInjury, poisoning and procedural complications1/431/511/23
Most frequent other events
Showing 10 of 33
Most frequent other events
Event400 µg Brimonidine Tartrate Implant200 µg Brimonidine Tartrate ImplantSham (no Implant) Stage 2
Conjunctival HaemorrhageEye disorders12/4321/512/23
HypertensionVascular disorders2/431/514/23
Conjunctival HyperaemiaEye disorders3/437/513/23
AnaemiaBlood and lymphatic system disorders1/435/513/23
NauseaGastrointestinal disorders0/433/513/23
Back PainMusculoskeletal and connective tissue disorders1/430/513/23
Punctate KeratitisEye disorders5/431/510/23
Eye PainEye disorders5/431/511/23
Urinary Tract InfectionInfections and infestations3/435/512/23
CataractEye disorders4/433/511/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)400 µg Brimonidine Tartrate Implant Stage 1200 µg Brimonidine Tartrate Implant Stage 1400 µg Brimonidine Tartrate Implant Stage 2200 µg Brimonidine Tartrate Implant Stage 2Sham (no Implant) Stage 2Total
Mean85.0 ± 3.6179.0 ± 3.0075.6 ± 8.7877.0 ± 9.1378.4 ± 5.8077.0 ± 8.33
Sex: Female, Male
Sex: Female, Male(Participants)400 µg Brimonidine Tartrate Implant Stage 1200 µg Brimonidine Tartrate Implant Stage 1400 µg Brimonidine Tartrate Implant Stage 2200 µg Brimonidine Tartrate Implant Stage 2Sham (no Implant) Stage 2Total
Female3227281272
Male0114211147
08

Study locations

7 sites
  • Abilene, Texas, United States
  • Sydney, New South Wales, Australia
  • Karlsruhe, Germany
  • Udine, Italy
  • Seoul, Korea, Republic of
  • Makati City, Philippines
  • Coimbra, Portugal
09

References and documents

Publications

  • Kuppermann BD, Patel SS, Boyer DS, Augustin AJ, Freeman WR, Kerr KJ, Guo Q, Schneider S, Lopez FJ; Brimo DDS Gen 1 Study Group. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina. 2021 Jan 1;41(1):144-155. doi: 10.1097/IAE.0000000000002789. PubMed 32134802 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2008 to primary completion in Jun 2010, 25 months.

Results were first posted in Apr 2013, 2 years 10 months after primary completion. A results delay was requested in Jun 2011.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 25 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2008
First posted
Apr 15, 2008
StartActual
May 1, 2008
Primary completionActual
Jun 1, 2010
CompletionActual
Apr 8, 2011
Results delay requested
Jun 30, 2011
Results first posted
Apr 26, 2013
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00658619
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Apr 15, 2008
Start date
May 1, 2008
Primary completion
Jun 1, 2010
Completion
Apr 8, 2011
Results posted
Apr 26, 2013
Last update
Aug 21, 2018

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion